Results 221 to 230 of about 21,604,258 (289)
Sex-based disparities in cardiovascular outcomes: real-world evidence following chimeric antigen receptor T-cell therapy. [PDF]
Bahar AR +6 more
europepmc +1 more source
Chimeric Antigen Receptor T-Cell Therapy: More Than an Anti-Cancer Drug. [PDF]
Schenk HCM +8 more
europepmc +1 more source
High versus low baseline CAR‐HEMATOTOX scores were associated with poorer safety and efficacy outcomes in patients with R/R B‐NHL who received odronextamab in the ELM‐1 and ELM‐2 studies. The CAR‐HEMATOTOX score may provide a readily available measure for identifying patients at risk of inferior clinical outcomes with odronextamab treatment.
Matthew Matasar +9 more
wiley +1 more source
Sweet-like syndrome secondary to chimeric antigen receptor T-cell therapy for multiple myeloma: a case report. [PDF]
Ouyang X +5 more
europepmc +1 more source
Real-world outcomes of bispecific antibody therapy after chimeric antigen receptor T-cell therapy in follicular lymphoma. [PDF]
Sharp J +13 more
europepmc +1 more source
Summary Comprehensive genome and transcriptome profiling can inform the diagnosis, prognosis and management of relapsed/refractory (R/R) solid malignancies, yet its integration into clinical care has lagged despite strong biological rationale. We evaluated the clinical utility of whole genome and transcriptome analysis (WGTA) in 65 patients (37 ...
Kathleen Wee +24 more
wiley +1 more source
Late Complications After European Medicines Agency-Approved Chimeric Antigen Receptor T-Cell Therapy in Hematological Malignancies: A Scoping Review. [PDF]
Eisenmann M, Zhu Z, Arndt V, Thong MSY.
europepmc +1 more source
Summary Patient‐reported outcome (PRO) and quality of life (QoL) assessments for multiple myeloma (MM) patients are traditionally collected at infrequent intervals using burdensome instruments, resulting in limited clinical visibility between visits. This creates a critical gap in care, as evolving symptoms and treatment‐related toxicities frequently ...
Victor Tellez +12 more
wiley +1 more source
Advancements in delivery systems for in vivo chimeric antigen receptor T-cell therapy in urological diseases. [PDF]
Li Y, Zhang W, Tang D.
europepmc +1 more source
Summary Venetoclax plus anti‐CD20 monoclonal antibody (mAb) regimens have revolutionised treatment for chronic lymphocytic leukaemia (CLL); however, CD20 antigen loss is a potential consequence. Given emerging roles for re‐treatment with venetoclax plus anti‐CD20 mAb and CD20‐targeting bispecific antibodies in CLL, we retrospectively assessed the ...
Tamasine Stewart +15 more
wiley +1 more source

